Indivior Pharmaceuticals, Inc. (INDV) Q3 2026 earnings results
Indivior Pharmaceuticals, Inc. (INDV) reported Q3 2026 results on Oct 29, 2026, 7:00:15 AM ET: adjusted EPS $1.32 vs. $1.13 expected (beat by 17.2%); revenue $356.00M vs. $329.35M expected (beat by 8.1%). Outlook: Indivior is on track to achieve its previously communicated full year 2026 guidance as a standalone organization.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (adjusted, diluted) | $1.32 | $1.13 | Beat by 17.2% |
| Revenue | $356.00M | $329.35M | Beat by 8.1% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Oct 29, 2026, 7:00:15 AM ET. Nexqual published them 38 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 13.4% from $314.00M.
Stock reaction
The results came out before the market opened. INDV closed at $35.25 on October 29, 2026, up 1.4% from its $34.77 close on October 28, 2026 before the results.
Questions and answers
Did Indivior Pharmaceuticals, Inc. beat earnings expectations?
Yes. Indivior Pharmaceuticals, Inc. reported adjusted EPS of $1.32 against an average analyst estimate of $1.13 (beat by 17.2%), and revenue of $356.00M against $329.35M expected (beat by 8.1%).
What were Indivior Pharmaceuticals, Inc.'s Q3 2026 earnings and revenue?
adjusted diluted EPS of $1.32 and revenue of $356.00M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 13.4% from $314.00M.
When did Indivior Pharmaceuticals, Inc. report Q3 2026 earnings?
Oct 29, 2026, 7:00:15 AM ET, in an SEC 8-K filing (Item 2.02).
How did INDV stock react to the earnings?
The results came out before the market opened. INDV closed at $35.25 on October 29, 2026, up 1.4% from its $34.77 close on October 28, 2026 before the results.
What did Indivior Pharmaceuticals, Inc. say about its outlook?
Indivior is on track to achieve its previously communicated full year 2026 guidance as a standalone organization.
More on INDV
INDV stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings October 29, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built October 29, 2026 at 23:07 UTC. Not investment advice.
Data source: Nexqual. Last updated: October 29, 2026 at 23:07 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt